Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 14;8(11):18296-18302.
doi: 10.18632/oncotarget.15433.

Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study

Jian-Hong Zhong  1   2 , Ning-Fu Peng  1   2 , Xue-Mei You  1   2 , Liang Ma  1   2 , Xiao Xiang  1 , Yan-Yan Wang  1 , Wen-Feng Gong  1   2 , Fei-Xiang Wu  1   2 , Bang-De Xiang  1   2 , Le-Qun Li  1   2
Affiliations

Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study

Jian-Hong Zhong et al. Oncotarget. .

Abstract

The current clinical reality of tumor stages and primary treatments of hepatocellular carcinoma (HCC) is poorly understood. This study reviewed the distribution of tumor stages and primary treatment modalities among a large population of patients with primary HCC. Medical records of patients treated between January 2003 and October 2013 for primary HCC at our tertiary hospital in China were retrospectively reviewed. A total of 6241 patients were analyzed. The distribution of Barcelona Clinic Liver Cancer (BCLC) stages was as follows: stage 0/A, 28.9%; stage B, 16.2%; stage C, 53.6%; stage D, 1.3%. The distribution of Hong Kong Liver Cancer (HKLC) stages was as follows: stage I, 8.4%; stage IIa, 1.5%; stage IIb, 29.0%; stage IIIa, 10.0%; stage IIIb, 33.6%; stage IVa, 3.4%; stage IVb, 2.5%; stage Va, 0.2%; stage Vb, 11.4%. The most frequent therapy was hepatic resection for patients with BCLC-0/A/B disease, and transarterial chemoembolization for patients with BCLC-C disease. Both these treatments were the most frequent for patients with HKLC I to IIIb disease, while systemic chemotherapy was the most frequent first-line therapy for patients with HKLC IVa or IVb disease. The most frequent treatment for patients with HKLC Va/Vb disease was traditional Chinese medicine. In conclusion, Prevalences of BCLC-B and -C disease, and of HKLC I to IIIb disease, were relatively high in our patient population. Hepatic resection and transarterial chemoembolization were frequent first-line therapies.

Keywords: hepatic resection; hepatocellular carcinoma; transarterial chemoembolization; treatment selection; tumor stage.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have declared that no competing interest exist.

Figures

Figure 1
Figure 1. Frequencies of different primary treatments among patients with primary hepatocellular carcinoma A. without stratification or B-C. with stratification, based on the (B) Barcelona Clinic Liver Cancer system or (C) Hong Kong Liver Cancer system
BSC, best supportive care; NT, no active treatment; RFA, radiofrequency ablation; RT, radiotherapy; SC, systemic chemotherapy; TACE, transarterial chemoembolization; TCM, traditional Chinese medicine.
Figure 2
Figure 2. Distribution of primary treatments among patients with hepatocellular carcinoma in different stages of the Barcelona Clinic Liver Cancer (BCLC) system: (A) stage A (n = 1805), (B) stage B (n = 1012), (C) stage C (n = 3348), (D) stage D (n = 76)
BSC, best supportive care; NT, no active treatment; RFA, radiofrequency ablation; RT, radiotherapy; SC, systemic chemotherapy; TCM, traditional Chinese medicine; TACE, transarterial chemoembolization.
See this image and copyright information in PMC

References

    1. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC) Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2014;2015;16:465–522. - PMC - PubMed
    1. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y. Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology. 2014;87:7–21. - PubMed
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - PubMed
    1. Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, Wu LY, He J. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res. 2012;24:171–180. - PMC - PubMed
    1. Zhang CY, Huang TR, Yu JH, Zhang ZQ, Li JL, Deng W, Ye SY, Zhou DN, He ZF. Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer. 2010;29:545–550. - PubMed